A phase IIa trial showed that peresolimab, an agonistic PD‐1 antibody, significantly improved DAS28‐CRP scores at 12 weeks compared with placebo in adults with moderate‐to‐severe RA who had an inadequate response to disease‐modifying antirheumatic drugs (DMARDs) [537]. This evidence concerns the gene CRP and rheumatoid arthritis.